| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
42,850,000 |
| Market
Cap: |
63.85(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.11 - $7.13 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 19.7 |
| Insider 3/6 Months : 20.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adicet Bio is a biopharmaceutical company discovering and developing allogeneic gamma delta T cell therapies for cancer. Co.'s product candidate, ADI-001, an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptors (CAR) targeting CD20, is in Phase 1 study for the treatment of Non-Hodgkin's Lymphoma. Co.'s pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15, for the treatment of solid tumors. In addition, Co. is engaged in preclinical stage activities directed to expansion of its pipeline of product candidates for both hematological malignancies and solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
6,250,000 |
8,016,000 |
8,016,000 |
| Total Buy Value |
$0 |
$15,000,000 |
$18,684,650 |
$18,684,650 |
| Total People Bought |
0 |
2 |
5 |
5 |
| Total Buy Transactions |
0 |
2 |
7 |
7 |
| Total Shares Sold |
0 |
0 |
11,000 |
232,611 |
| Total Sell Value |
$0 |
$0 |
$15,291 |
$3,870,940 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
2 |
19 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gordon Carl L |
Director |
– • • |
2021-12-10 |
4 |
A |
$14.00 |
$2,999,990 |
I/I |
214,285 |
242,285 |
|
- |
|
| Orbimed Israel Biofund Gp Limited Partnership |
Director |
– • • |
2021-12-10 |
4 |
A |
$14.00 |
$2,999,990 |
I/I |
214,285 |
242,285 |
|
- |
|
| Sinclair Andrew |
Director |
– • – |
2021-12-08 |
4/A |
B |
$14.00 |
$7,000,000 |
I/I |
500,000 |
2,115,385 |
2.1 |
- |
|
| Sinclair Andrew |
Director |
– • – |
2021-12-08 |
4 |
B |
$14.00 |
$7,000,000 |
I/I |
500,000 |
2,140,721 |
2.1 |
0% |
|
| Aftab Blake |
Chief Scientific Officer |
• – – |
2021-10-12 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
80,000 |
|
- |
|
| Schor Chen |
President & CEO |
• • – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
240,000 |
240,000 |
|
- |
|
| Galimi Francesco |
SVP & Chief Medical Officer |
• – – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
86,983 |
|
- |
|
| Healey Don |
Chief Technology Officer |
• – – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
80,000 |
|
- |
|
| Harvey Brian Nicholas |
Chief Financial Officer |
• – – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
80,000 |
|
- |
|
| Schor Chen |
President & CEO |
• • – |
2021-06-16 |
4 |
AS |
$10.53 |
$173,443 |
I/I |
(16,466) |
89,836 |
|
-22% |
|
| Jakobovits Aya |
Director |
– • – |
2021-06-15 |
4 |
AS |
$11.16 |
$42,919 |
I/I |
(3,847) |
215,883 |
|
-22% |
|
| Galimi Francesco |
SVP & Chief Medical Officer |
• – – |
2021-06-04 |
4 |
OE |
$5.97 |
$41,689 |
D/D |
6,983 |
6,983 |
|
- |
|
| Schor Chen |
President & CEO |
• • – |
2021-06-03 |
4 |
AS |
$12.06 |
$198,499 |
I/I |
(16,466) |
98,818 |
|
-39% |
|
| Jakobovits Aya |
Director |
– • – |
2021-05-20 |
4 |
AS |
$14.23 |
$25,498 |
I/I |
(1,792) |
217,806 |
|
-45% |
|
| Schor Chen |
President & CEO |
• • – |
2021-05-19 |
4 |
AS |
$13.42 |
$221,436 |
I/I |
(16,466) |
107,800 |
|
-39% |
|
| Jakobovits Aya |
Director |
– • – |
2021-05-18 |
4 |
AS |
$14.05 |
$87,249 |
I/I |
(6,208) |
218,706 |
|
-43% |
|
| Jakobovits Aya |
Director |
– • – |
2021-05-12 |
4 |
AS |
$13.23 |
$132,333 |
I/I |
(10,000) |
221,806 |
|
-47% |
|
| Schor Chen |
President & CEO |
• • – |
2021-05-05 |
4 |
AS |
$13.90 |
$234,222 |
I/I |
(16,466) |
116,782 |
|
-47% |
|
| Schor Chen |
President and CEO |
• • – |
2021-04-20 |
4 |
AS |
$12.01 |
$197,676 |
I/I |
(16,466) |
104,777 |
|
-33% |
|
| Schor Chen |
President and CEO |
• • – |
2021-04-06 |
4 |
AS |
$13.04 |
$214,700 |
I/I |
(16,466) |
112,261 |
|
-41% |
|
| Schor Chen |
President and CEO |
• • – |
2021-03-30 |
4 |
AS |
$12.30 |
$211,640 |
I/I |
(16,466) |
119,745 |
|
-46% |
|
| Schor Chen |
President and CEO |
• • – |
2021-03-16 |
4 |
AS |
$15.07 |
$252,558 |
I/I |
(16,466) |
127,229 |
|
-52% |
|
| Sinclair Andrew |
Director |
– • – |
2021-03-02 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
1,615,385 |
|
- |
|
| Sinclair Andrew |
Director |
– • – |
2021-03-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,640,721 |
|
-43% |
|
| Chimovits Erez |
Director |
– • • |
2021-02-12 |
4 |
A |
$13.00 |
$6,816,537 |
I/I |
524,349 |
396,657 |
|
- |
|
165 Records found
|
|
Page 5 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.10 (6.29%) 
